All In Biotech

NDA 022565 · Haleon US Holdings

Advil Congestion Relief

Ibuprofen, Phenylephrine Hydrochloride · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Nov 19, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

May 27, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

998

15 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2025.

Uses temporarily relieves these symptoms associated with the common cold or flu: headache fever sinus pressure nasal congestion minor body aches and pains reduces swelling of the nasal passages temporarily restores freer breathing through the nose

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ADVIL CONGESTION RELIEF · IBUPROFEN 200MG; PHENYLEPHRINE HYDROCHLORIDE 10MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication289
  • drug ineffective257
  • drug effective for unapproved indication255
  • drug effect incomplete91
  • therapeutic product effect incomplete67
  • therapeutic response unexpected49
  • drug ineffective for unapproved indication48
  • pre-existing condition improved45
  • somnolence42
  • product use issue28
  • drug effect less than expected24
  • feeling abnormal19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2015218
2016131
201779
201823
201943
202011
2021456
202215
20237
20246
20254
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,679 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.